ExodusPoint Capital Management LP Sells 147,957 Shares of Natera, Inc. (NASDAQ:NTRA)

ExodusPoint Capital Management LP lessened its stake in Natera, Inc. (NASDAQ:NTRA) by 82.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,471 shares of the medical research company’s stock after selling 147,957 shares during the quarter. ExodusPoint Capital Management LP’s holdings in Natera were worth $4,982,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in NTRA. Blue Trust Inc. increased its stake in shares of Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc lifted its holdings in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after acquiring an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 261 shares in the last quarter. Principal Securities Inc. increased its holdings in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after buying an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its stake in shares of Natera by 1,328.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock valued at $57,000 after acquiring an additional 332 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Trading Down 3.5 %

NTRA opened at $133.87 on Friday. The stock has a 50-day moving average of $156.81 and a 200 day moving average of $151.40. The firm has a market cap of $18.10 billion, a P/E ratio of -76.06 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $476.10 million during the quarter, compared to analysts’ expectations of $447.91 million. As a group, research analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Insiders Place Their Bets

In other Natera news, CFO Michael Burkes Brophy sold 2,562 shares of the business’s stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $138.41, for a total value of $354,606.42. Following the completion of the transaction, the chief financial officer now directly owns 75,557 shares in the company, valued at approximately $10,457,844.37. The trade was a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Solomon Moshkevich sold 24,861 shares of the stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $4,101,319.17. Following the sale, the insider now directly owns 140,684 shares of the company’s stock, valued at approximately $23,208,639.48. The trade was a 15.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 325,922 shares of company stock worth $51,603,664 in the last ninety days. 7.60% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on NTRA. Morgan Stanley upped their price objective on Natera from $176.00 to $185.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Guggenheim increased their price objective on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a report on Wednesday, March 19th. Canaccord Genuity Group reissued a “buy” rating and set a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Natera in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.